SCHEMBL6982894

SCHEMBL6982894

O=c1[nH]c2ccccc2c(=O)n1Cc1ccccc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 5/20 1.00
ALDH1A1 P00352 4/20 1.00
KDM4E B2RXH2 4/20 1.00
SMN1; SMN2 Q16637 3/20 1.00
MEN1 O00255 3/20 0.74
KMT2A Q03164 3/20 0.74
CYP1A2 P05177 1/20 0.68
TSHR P16473 1/20 0.64
LMNA P02545 3/20 0.60
MAPK10 P53779 3/20 0.60
HSD17B10 Q99714 2/20 0.60
USP2 O75604 1/20 0.60
NPSR1 Q6W5P4 1/20 0.60
ACHE P22303 1/20 0.60
MAPK1 P28482 1/20 0.60
HDAC1 Q13547 1/20 0.60
NPC1 O15118 1/20 0.57
RAB9A P51151 1/20 0.57
TP53 P04637 1/20 0.57
POLB P06746 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30877025 1.00 HPGD (1.00) HPGDALDH1A1KDM4ESMN1; SMN2MEN1
SCHEMBL19291210 0.89 HPGD (0.80) HPGDALDH1A1KDM4ESMN1; SMN2MEN1
SCHEMBL1067505 0.89 HPGD (0.78) HPGDALDH1A1KDM4ESMN1; SMN2MEN1
SCHEMBL10487828 0.85 HPGD (0.74) HPGDALDH1A1KDM4ESMN1; SMN2MEN1
SCHEMBL7593290 0.85 MEN1 (0.77) HPGDALDH1A1KDM4ESMN1; SMN2MEN1
SCHEMBL6295507 0.85 MEN1 (1.00) HPGDALDH1A1KDM4ESMN1; SMN2MEN1
SCHEMBL7101724 0.85 KMT2A (0.78) HPGDALDH1A1KDM4ESMN1; SMN2MEN1
SCHEMBL6980977 0.84 PKM (0.79) HPGDALDH1A1KDM4ESMN1; SMN2MEN1
SCHEMBL6976707 0.83 SMN1; SMN2 (0.76) HPGDALDH1A1KDM4ESMN1; SMN2MEN1
SCHEMBL12821913 0.83 HPGD (0.70) HPGDALDH1A1KDM4ESMN1; SMN2MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024091450-A1 COMPOUNDS AND METHODS FOR TREATING CANCER THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2024-05-02 WO disclosed
US-20210220331-A1 INHIBITORS OF IRES-MEDIATED PROTEIN SYNTHESIS THE UNITED STATES GOVERNMENT REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS 2021-07-22 US disclosed
EP-3452447-A1 INHIBITORS OF IRES-MEDIATED PROTEIN SYNTHESIS The Regents of The University of California (US) 2019-03-13 EP disclosed
WO-2017192665-A1 INHIBITORS OF IRES-MEDIATED PROTEIN SYNTHESIS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2017-11-09 WO disclosed
US-20030199530-A1 New compounds derived from quinazoline LES LABORATORIES SERVIER (FR) 2003-10-23 US disclosed
EP-1346992-A1 Quinazoline derivatives, process for their preparation and pharmaceutical compositions containing them Les Laboratoires Servier (FR) 2003-09-24 EP disclosed
US-5710319-A Process for the preparation of substituted quinazoline-2,4-diones HOECHST AKTIENGESELLSCHAFT (DE) 1998-01-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030199530-A1 New compounds derived from quinazoline NQO2, XDH, DRD1 HPGD 1378/4885ALDH1A1 331/4885KDM4E 4217/4885
US-20210220331-A1 INHIBITORS OF IRES-MEDIATED PROTEIN SYNTHESIS EIF4EBP1, EIF4E, EIF2A HPGD 3898/4885ALDH1A1 4611/4885KDM4E 1896/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.